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Abstract 
Background: Cell loss and subsequent deterioration of contractile function are hallmarks of chronic heart failure 
(HF). While apoptosis has been investigated as a participant in the progression of HF, it is unlikely that it accounts for 
the total amount of non-functional tissue. In addition, there is evidence for the presence of necrotic cardiomyocytes 
in HF. Therefore, the objective of this study was to investigate the necroptotic proteins regulating necroptosis, a form 
of programmed necrosis, and thereby assess its potential role in human end-stage HF.
Methods: Left ventricular samples of healthy controls (C) and patients with end-stage HF due to myocardial infarc-
tion (CAD) or dilated cardiomyopathy (DCM) were studied. Immunoblotting for necroptotic and apoptotic markers 
was performed. Triton X-114 fractionated samples were analyzed to study differences in subcellular localization.
Results: Elevated expression of RIP1 (receptor-interacting protein),  pSer227-RIP3 and its total levels were observed 
in HF groups compared to controls. On the other hand, caspase-8 expression, a proapoptotic protease negatively 
regulating necroptosis, was downregulated suggesting activation of necroptosis signaling. Total mixed-lineage kinase 
domain-like protein (MLKL) expression did not differ among the groups; however, active cytotoxic forms of MLKL 
were present in all HF samples while they were expressed at almost undetectable levels in controls. Interestingly, 
 pThr357-MLKL unlike  pSer358-MLKL, was higher in DCM than CAD. In HF, the subcellular localization of both RIP3 and 
 pThr357-MLKL was consistent with activation of necroptosis signaling. Expression of main apoptotic markers has not 
indicated importance of apoptosis.
Conclusions: This is the first evidence showing that human HF of CAD or DCM etiology is positive for markers of 
necroptosis which may be involved in the development of HF.
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Background
Progressive cell death resulting in functional impairment 
of the myocardium is a characteristic feature of chronic 
heart failure (HF). Since regenerative capabilities of the 
heart are limited the most crucial factor determining 
cardiac function in this pathological process is the num-
ber of viable functional cardiomyocytes [1]. Therefore, 
understanding which cell death modalities underlie HF-
associated cell loss is of a prime importance in order to 
devise effective pharmacological interventions. Presence 
of apoptosis, a prominent constituent of the programmed 
cell death group, in HF has been reported both in clini-
cal and experimental studies [2, 3]. However, the observed 
percentage of apoptosis positive cells (0.1–0.8%) is likely 
to be too low to explain the majority of cell death occur-
ring during HF [1, 3, 4]. On the other hand, the relevance 
of cardiomyocyte necrosis, another major type of cell 
death, in HF is poorly defined. Of note, some reports have 
shown that necrotic cardiomyocytes significantly out-
number the apoptotic ones, at least in end-stage HF [1, 
5]. Current knowledge about necrosis has been advanced 
and it has been suggested that necrotic processes are 
orchestrated by strictly regulated signaling pathways [6]. 
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The most thoroughly described subtype of programmed 
necrosis is necroptosis which depends on the presence of 
receptor-interacting protein kinase 1 and 3 (RIP1, RIP3) 
and mixed-lineage domain-like protein (MLKL) [6]. Exact 
execution mechanisms of necroptosis are still a matter of 
investigation; contemporary data implicate that MLKL 
phosphorylation at  Thr357/Ser358 and oligomerization, 
secondary to RIP1 and RIP3 activation, leads to mem-
brane permeabilization, ionic dysbalance, oncosis and 
subsequent cell rupture [7, 8]. Unlike apoptosis, necropto-
sis is a completely caspase-independent form of cell death; 
however, caspase-8 (csp-8) is known to indirectly regulate 
necroptosis activation in a negative manner. In fact, cleav-
age of RIP1 and RIP3 by caspase-8 prevents necroptotic 
signaling while simultaneously promoting apoptosis [6]. 
The importance of necroptosis has been shown mainly in 
non-cardiac pathologies [9] and recently, it has also been 
demonstrated in rodent reperfused hearts subjected to 
previous acute global and regional ischemia [10, 11] as 
well as in a model of cardiomyopathy [12, 13]. Relevance 
and proposed mechanisms of necroptotic cell death in 
heart failure have been reviewed elsewhere [14]. However, 
there is essentially no experimental evidence about its role 
in failing hearts irrespective of origin. Therefore, here we 
analyzed the expression of RIP1,  pSer227-RIP3, RIP3 and 
cytotoxic phosphorylated forms of MLKL  (pThr357-MLKL 
and  pSer358-MLKL) in human myocardium from end-
stage HF patients due to cardiomyopathy post myocardial 
infarction (CAD) and dilated cardiomyopathy (DCM). 
The extent of necroptosis in these types of HF was com-
pared to that of healthy control hearts. In addition, to pro-
vide a more complex picture of the signaling environment 
for necroptosis, we looked at the main negative regulator 
of necroptosis, csp-8, as well as certain apoptotic proteins.
Methods
Human samples
Samples of left ventricles (LVs) from failing hearts were 
obtained from hearts explanted during cardiac trans-
plantation. Care was taken to ensure to avoid fibrotic, 
vascular and adipose tissue. Right after excision the sam-
ples were rinsed, blotted to dryness and snap-frozen in 
liquid nitrogen. Excised samples were kept at −80 °C for 
long-term storage. In total 6 samples of failing hearts of 
ischemic etiology, 10 samples of failing hearts due to and 
4 control samples (C) were employed in the study. All HF 
patients were of New York Heart Association (NYHA) 
class III–IV. Control samples were obtained from healthy 
donors aged 22–44  years, whose hearts could not be 
used for transplantation due to medical or technical 
reasons. They received dopamine (1.5–3  µg/kg/min) as 
well as fluids/colloids before harvest and presented pre-
served systolic/diastolic function in echocardiographic 
examination. Patient characteristics (Additional file  1: 
Table S1) are described in the additional files.
Western blotting
Left ventricle homogenates were prepared from fro-
zen human heart samples. Samples were homogenized 
in RIPA buffer (Tris 65  mmol/l NaCl 150  mmol/l, 
 Na2H2EDTA 1  mmol/l, Triton X-100 1% v/v, Na-
deoxycholate 0.5% w/v, SDS 0.1% v/v, glycerol 5% v/v, 
pH  =  7.4) with protease and phosphatase inhibitors 
and protein concentration was determined with Lowry 
method. 15  µg of total protein per sample mixed with 
2× sample buffer (Tris–HCl pH =  7.6 40 mmol/l, glyc-
erol 20% v/v,  Na2H2EDTA 1 mmol/l, Bromophenol Blue 
0.01% w/v, SDS 2% w/v) was treated with 100 mM 2-mer-
captoethanol at 60  °C for 20  min, separated on 10 or 
12% Bis–Tris or Tris-Tricine SDS-PAGE gels and trans-
ferred onto polyvinylidene difluoride membranes (PVDF; 
0.45  µm pore size; Immobilon-P, Millipore, USA). For 
immunodetection, the following primary antibodies were 
used: anti-RIP1 (1:1000, SAB3500420, Sigma-Aldrich, 
USA), anti-phospho-Ser227-RIP3 (1:1000, ab209384, 
Abcam, UK), anti-RIP3 (1:3000, ARP32835, Aviva Sys-
tems Biology, USA), anti-MLKL (1:750, MABC604, Mil-
lipore, USA), anti-phosphoThr357-MLKL (1:500, ABC234, 
Millipore, USA), anti-phosphoThr358-MLKL (1:1000, 
ab187091, Abcam, UK), anti-Bcl-2 (1:2000, SAB4500003, 
Sigma-Aldrich, USA), anti-Bax (1:1000, #2772, Cell Sign-
aling Technology, USA), anti-PARP1 (1:1000, #9532, Cell 
Signaling Technology, USA), anti-PARP1p25 (1:1000, 
ab32064, Abcam, UK), anti-caspase-3 (1:1000, sc-98785, 
Santa Cruz Biotechnology, USA), anti-cleaved caspase-3 
[5A1E] (1:500, #9664, Cell Signaling Technology, USA), 
anti-caspase-7 (1:1000, #12827, Cell Signaling Technol-
ogy, USA), anti-caspase-8 (1:2000, 04-573, Millipore, 
USA), anti-GAPDH HRP conjugate (1:25000, G9295, 
Sigma-Aldrich, USA), anti-COXIV isoform 1 (1:1000, 
AV42784, Sigma-Aldrich, USA). Secondary antibod-
ies used were: donkey anti-rabbit IgG-HRP (1:50000-
1:100000, NA934  V, GE Healthcare Life Sciences, UK), 
mouse anti-rabbit light chain specific IgG-HRP (1:50000, 
211-032-171, Jackson Immunoresearch, USA), goat anti-
rat light chain specific IgG-HRP (1:50000, 112-035-175, 
Jackson Immunoresearch, USA). Signals generated with 
an enhanced chemiluminescence kit (Luminata Cre-
scendo, Millipore, USA) were captured with a phospho-
rescence imager (myECL Imager, Thermo Scientific, 
USA) and quantified with myECL Image Analysis soft-
ware (version 1.1, Thermo Scientific, USA). Total pro-
tein staining of membranes with Ponceau S (0.2% w/v in 
3% w/v trichloroacetic acid) or Coomassie Brilliant Blue 
G-250 (0.25% w/v in 50% v/v isopropanol) evaluated by 
scanning densitometry was used as the loading control 
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instead of housekeeping protein immunodetection [15–
17]. All used chemicals were sourced from Sigma-Aldrich 
(USA), Alfa-Aesar (USA), SERVA (GER), CentralChem 
(SK) and Merck (USA).
Statistical analysis
All data are presented in the form mean ± standard error. 
Group differences in measured parameters were tested 
with one-way ANOVA and unpaired two-tailed t test 
with or without Welch’s correction (based on results of 
F test for unequal variances). All statistical analysis was 
performed with GraphPad Prism version 6.00 for Win-
dows (GraphPad Software, USA). Differences between 
groups were considered to be significant when P < 0.05.
Results
Pro‑necroptotic markers in HF patients are elevated 
compared to controls
The protein expression of some major mediators of 
necroptotic cell death in LVs of HF patients is shown 
in Fig. 1a–i. RIP1 and RIP3 expression as well its active 
form phosphorylated on  Ser227 were significantly 
elevated in both CAD and DCM hearts, thereby indicat-
ing necroptosis induction (Fig. 1b–d). In addition, active 
csp-8, was severely decreased in HF samples (Fig.  1f ). 
Interestingly though, this decrease could be solely 
explained through downregulation of procsp-8 expres-
sion rather than by its reduced cleavage (Fig. 1e) as csp-8/
procsp-8 ratio was unchanged compared to controls 
(Fig.  1g). Total MLKL expression did not significantly 
differ among tested groups (Fig.  1h). Importantly, both 
key terminal markers of necroptosis,  pThr357-MLKL and 
 pSer358-MLKL, were present in all HF samples while they 
were expressed at almost undetectable levels in controls 
(Fig.  1i, j). Moreover,  pThr357-MLKL expression, unlike 
 pSer358-MLKL was significantly higher in DCM hearts 
than CAD ones. However, the molecular weight of the 
observed band was 100-110  kDa suggesting dimer for-
mation. As MLKL oligomerization post phosphorylation 
should involve trimer, tetramer or hexamer formation 
with possible translocation into cellular membranes [7], 
antibody non-specificity was also suspected even though 
the observed pattern was concordant with our hypoth-
esis. Therefore, in order to support these findings, we 
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Fig. 1 Activation of necroptotic pathway in human end-stage heart failure. a Representative immunoblots of RIP1, RIP3,  pSer227-RIP3, procsp-8, csp-
8, MLKL,  pSer358-MLKL and  pThr357-MLKL in control (C) and heart failure due to myocardial infarction (CAD) or dilated cardiomyopathy (DCM). The 
right RIP3 blot and its corresponding total protein stain section are spliced because of marker lane interference. b–f, h–j Quantification of RIP1, RIP3, 
 pSer227–RIP3, procsp-8, csp-8, MLKL,  pSer358-MLKL and  pThr357-MLKL immunoblots. g Quantification of procsp-8/csp-8 ratio. Data are presented as 
mean ± SEM. *P < 0.05 vs. C; #P < 0.05 vs. CAD. n = 4, 6, 10 for C, CAD and DCM respectively. ND non-detectable
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performed a subcellular fractionation with Triton X-114 
(Additional file 1: Figure S1A–G). Due to limited amount 
of human heart tissue, the analysis was performed with 
pooled samples only and thus differences among groups 
could not be analyzed statistically. As shown in Figure 
S1A,  pThr357-MLKL signal was detected  ~100  kDa on 
top of MLKL (Additional file  1: Figure S1B,C) in CAD 
and DCM samples but not in controls. These findings are 
consistent with those from whole tissue lysates. Of note, 
the signal was present in aqueous and insoluble frac-
tions. Whether this signal represents a dimer or some 
post-translationally modified form of MLKL remains to 
be determined. Unlike  pThr357-MLKL, RIP3 was detected 
in all tested fractions with notable increases in cytoplasm 
and membrane compartments of HF samples as would 
be expected for active necroptosis (Additional file 1: Fig-
ure S1D). No discernible pattern of distribution could be 
seen for RIP1 (Additional file 1: Figure S1E).
Lack of apoptosis in end‑stage heart failure
Expression of apoptotic markers is summarized in 
Fig.  2a–m. Bcl-2 levels were lower in both HF groups; 
however, only the comparison of C vs. CAD reached 
significance (Fig.  2b). Bax was found to be essentially 
unchanged in both HF groups (Fig.  2c). These changes 
were reflected in the Bcl-2/Bax ratio (Fig.  2d). Cas-
pase-3 (csp-3) displayed a significant decrease in DCM 
compared to controls (Fig. 2f ) while this effect was lost 
when csp-3/procsp-3 ratio was quantified (Fig.  2g). 
Active caspase-7 (csp-7) expression was significantly 
downregulated in all failing hearts irrespective of the 
etiology while procsp-7 and csp-7/procsp-7 did not dif-
fer among the groups (Fig.  2h–j). In addition to these 
apoptotic markers, we analyzed PARP1, one of the prin-
cipal targets of active csp-3 and csp-7 [18]. Total PARP1 
was comparable in all groups (Fig.  2m). However, p89 
fragment with reduced DNA binding capacity, a sensi-
tive marker for apoptosis [19], could not be detected 
in any of the samples with the antibody used while its 
counterpart apoptotic DNA repair enzyme inhibit-
ing p25 fragment (N terminal peptide) did not differ in 
failing hearts (Fig. 2l). Other fragments of PARP1 with 
uncertain identity could be identified at ~70, ~55, ~40 
and  ~35  kDa. The expression of the first 3 fragments 
did not differ among the groups. On the other hand, 
the 35 kDa fragment, which is associated with µ-calpain 
activity [18], was significantly upregulated in both HF 
groups (Fig. 2k).
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Fig. 2 Lack of significant changes in the expression of apoptotic markers in human end-stage heart failure. a Representative immunoblots of Bcl-2, 
Bax, procsp-3, csp-3 and PARP1 in control (C) and heart failure samples due to myocardial infarction (CAD) and dilated cardiomyopathy (DCM). The 
right PARP1 blot and its corresponding total protein stain section are spliced because of marker lane interference. b, c, e, f, h–m Quantification of 
Bcl-2, Bax, procsp-3, csp-3, procsp-7, csp-7, PARP1 p35, PARP1 p25 and total PARP1 immunoblots. d, g Quantification of Bcl-2/Bax, csp-3/procsp-3 
and csp-7/procsp-7 ratios. Data are presented as mean ± SEM. *P < 0.05 vs. C. n = 4, 6, 10 for C, CAD and DCM respectively
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Discussion
In this study, we have indicated for the first time that (i) 
left ventricular samples of human HF are characterized 
by elevated expression of major factors of necroptosis 
induction, (ii) DCM is characterized by a higher expres-
sion of a main executive necroptotic protein—pThr357-
MLKLas compared to CAD and (iii) that these main 
proteins of necroptotic cell death outweigh the apoptotic 
pathway.
Both HF groups showed upregulation of RIP1 and 
RIP3. However, as these protein kinases (mainly RIP1) 
exhibit constitutive activity [6] their upregulation does 
not definitively indicate necroptosis. Therefore, active 
pronecroptotic forms of proteins of RIP1-RIP3 axis, 
should be presented to support findings about the pres-
ence of necroptosis in diseased tissue. To follow this 
approach, we analyzed tissue expression of  pSer227-RIP3, 
a useful necroptotic marker which has been suggested to 
be present during active necroptosis [20].  pSer227-RIP3 
was highly elevated in all failing hearts irrespective of 
the etiology suggesting that RIP3 and its phosphoryla-
tion could be involved in human HF necroptosis. Indeed, 
a critical role of RIP3 in the myocardial necroptotic 
cascade has been demonstrated in the work of Luedde 
et  al. [12] and further supported by another study [13]. 
In fact, mice deficient in RIP3 have shown significantly 
improved ejection fraction, less hypertrophy and inflam-
matory response after permanent coronary artery liga-
tion. Furthermore, RIP3 activation has been indicated 
to be essential for activation of CaMKII with subse-
quent mPTP opening and induction of cell death of 
necrotic phenotype. It can be mentioned that this axis of 
RIP3-dependent necroptosis was found in both I/R and 
doxorubicin-induced cardiotoxicity [13], animal model 
analogues to types of heart failure referred to in our 
study. The involvement of this protein kinase, a key regu-
lator of  Ca2+ homeostasis in cardiomyocytes in myocar-
dial I/R-induced necroptosis, has also been proposed in 
our recent study showing that the inhibition of CaMKII 
reversed certain changes in pronecroptotic markers what 
was accompanied by improved contractile function [10]. 
It should be noted, however, that the pronecroptotic axis 
involving RIP3-CaMKII resulting in cell death via effects 
on mitochondria [13] is contradictory to studies showing 
that necroptosis occurs due to plasma membrane disrup-
tion as a consequence of recruitment of MLKL following 
RIP1-RIP3 activation [7, 12, 20].
Here, we have also found that the expression of csp-
8, a negative regulator of necroptosis, was significantly 
downregulated in end-stage HF. Furthermore, we have 
investigated a specific molecular marker of necropto-
sis execution which until very recently was impossible 
to probe for. However, this fact changed with MLKL 
phosphorylation at  Thr357 or  Ser358 being described as a 
crucial terminal marker of necroptosis [7, 21, 22]. Only 
one of these residues has been shown to be essential for 
necroptosis execution [23]. In fact, this post-transla-
tionally modified form of MLKL has been found to oli-
gomerize (however, the number of monomers required 
for oligomer assembly is still a subject of investigation), 
translocate into the cellular membrane and thereby alter 
the influx of ions, mainly  Na+ and  Ca2+, or increase non-
specific membrane permeability [7, 21, 22]. Thus, disrup-
tion in ion homeostasis leading in cell oncosis has been 
proposed to underlie the cytotoxic action of phospho-
MLKL. In this study, these cytotoxic forms of MLKL 
phosphorylated at  Thr357 and  Ser358 were detectable in 
all HF samples supporting the implication of RIP1, RIP3 
and p-Ser227-RIP3 expression data and the hypothesis 
that this cell death mode might be involved in the patho-
genesis of HF [11]. These results are further supported by 
data obtained from Triton X-114 fractionation which has 
revealed the presence of this critical necroptotic marker 
in phases representing the cytoplasm, nuclei and possi-
bly lipid rafts [24]. This may indicate that the execution 
of necroptosis in end-stage HF is not restricted to only 
cytoplasm and membranes but also may involve the 
nucleus. The suggested nuclear translocation is in agree-
ment with very recent findings reported from the colo-
rectal cell line HT29 [25].
According to available knowledge about the regula-
tion of programmed cell death types, when necroptosis 
is not being activated the pathways default to apoptotic 
processes usually by the means of csp-8 [6]. Indeed, the 
inhibition or depletion of this caspase has been shown 
to inhibit apoptosis while promoting necroptosis and, 
analogously, active csp-8 leads to cleavage of RIP1 and 
RIP3 which subsequently promotes apoptosis and pre-
vents necroptosis [26]. Since csp-8 was found to be sig-
nificantly downregulated, our data support the statement 
that apoptosis is unlikely to be significantly increased 
in human end-stage HF [2, 27, 28] and that necropto-
sis, rather than apoptosis itself, might be critical for the 
determination of a number of viable cells in HF [14]. It 
can be mentioned that the observed downregulation 
of csp-8 seems to be an effect attributable to reduced 
procsp–8 expression and not its cleavage. While we did 
not seek an explanation for this novel csp-8 related find-
ing, a  plausible link between procsp–8 downregulation, 
necroptosis and miR-874 has been recently described 
in cardiomyocytes [29]. In line with the theoretical 
paradigm and our hypothesis about increased necrop-
tosis at the expense of apoptosis in HF, we have shown 
that protein expression of main apoptotic markers was 
either mostly unchanged or reduced. Indeed, the levels 
of Bax, a proapoptotic protein, were unchanged while 
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expression of Bcl-2, counterbalancing the effects of Bax, 
was decreased or unchanged in failing hearts. Impor-
tantly, increased PARP1 apoptotic fragmentation does 
not seem to occur in these diseased hearts. In fact, an 
89 kDa fragment (C-terminal) with reduced DNA bind-
ing capacity released into the cytosol from the nucleus 
after cleavage could not be detected [30]. The second 
part of PARP1 produced during apoptotic processing, 
a 25 kDa fragment known to be retained in the nucleus 
where it inhibits the active DNA repairing PARP1 [31], 
could be detected but did not differ among the sam-
ples. This cleavage of PARP1 producing 25 and 89  kDa 
fragments is mediated by executioner caspases csp-3 
and csp-7 [18] expression of which was unchanged or 
decreased depending on the type of heart failure. Thus, 
these data referring to apoptotic pathway indicate that 
this particular regulated cell death does not play a major 
role in pathogenesis of HF. Studies of others [2–5, 27, 32, 
33] are in line with our report arguing against the impor-
tance of apoptosis in HF. On the other hand, it should be 
also noticed that some studies present the argument that 
even a small percentage of apoptotic cardiac myocytes is 
sufficient to induce heart failure [32, 33].
Conclusions
Our results provide the first evidence of either increased 
expression or selective presence of necroptotic proteins 
in human end-stage HF, which indicate both necrop-
tosis activation and execution. Although both of the 
active cytotoxic phosphorylated forms of MLKL were 
upregulated in failing hearts irrespective of the etiology, 
 pThr357-MLKL levels were higher in DCM than in CAD 
hearts. Complex analysis of major apoptotic proteins 
has not revealed a defining role of apoptotic cell death in 
the pathomechanisms of this disease (Fig.  3). By taking 
into consideration the fact that necroptosis, like any cell 
death, limits the number of functional cardiomyocytes, 
it can be assumed that these changes might also under-
lie the depressed function of failing hearts. In addition, it 
can also be suggested that interfering with RIP1-pSer227-
RIP3-phospho-MLKL signaling might be a pharmacolog-
ical intervention worth pursuing to prevent or retard the 
progression of HF.
Limitations
The main limitation of the study is that our conclusions 
are only based on protein data. However, our goal was 
to examine if there are differences in necroptotic pro-
teins depending on the etiology of heart failure, what 
is a completely new view onto the pathology of the 
disease. Likewise, patients with HF were treated with 
several drugs (beta-blockers, angiotensin-converting 
enzyme inhibitors, diuretics, etc.), while healthy control 
subjects were not given this chronic medication. In the 
human studies like this, this factor cannot be selectively 
excluded.
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